Arcutis Biotherapeutics' Application for Seborrheic Dermatitis Treatment Gets FDA Approval
Provided by
Dow Jones
By Denny Jacob
Arcutis Biotherapeutics' new drug application for zoryve topical foam as a treatment for seborrheic dermatitis received approval from the Food and Drug Administration.
The early commercial-stage company said the zoryve's approval is for the treatment of seborrheic dermatitis in people ages nine years and older.
Arcutis intends to make zoryve foam widely available through wholesaler and dermatology pharmacy channels as a new treatment option by the end of January.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
December 15, 2023 17:34 ET (22:34 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Q4 Stock Market Outlook: Where We See Opportunities for Investors
-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
This Cheap Stock Is Still a Buy Even After 50% Rally
-
10 Top-Performing Dividend Stocks of Q3 2024
-
33 Undervalued Stocks
-
Communication Services: Cable’s Broadband Dominance Isn’t as Strong as It Once Was
-
Technology: Strength Continues, With Software Presenting the Best Buying Opportunities
-
Best- and Worst-Performing Stocks of Q3 2024
-
Top Stocks to Own From the Best Fund Managers
-
2 Cheap Stocks Top Managers Have Been Buying
United States